Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐up
暂无分享,去创建一个
Mats Fredrikson | Mattias Ekstedt | Stergios Kechagias | M. Fredrikson | R. Hultcrantz | M. Ekstedt | S. Kechagias | H. Hagström | P. Nasr | P. Stål | Patrik Nasr | Per Stål | Rolf Hultcrantz | Hannes Hagström
[1] J. Takeda,et al. Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease. , 2007, World journal of gastroenterology.
[2] Rocio Lopez,et al. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis , 2010, Hepatology.
[3] R. Fisher,et al. Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values , 2003, Hepatology.
[4] N. Chalasani,et al. Endpoints and clinical trial design for nonalcoholic steatohepatitis , 2011, Hepatology.
[5] Enzo Bonora,et al. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. , 2010, The New England journal of medicine.
[6] M. Ekstedt,et al. Low clinical relevance of the nonalcoholic fatty liver disease activity score (NAS) in predicting fibrosis progression , 2012, Scandinavian journal of gastroenterology.
[7] R. Hultcrantz,et al. Patients with persistent elevation of aminotransferases: investigation with ultrasonography, radionucleide imaging and liver biopsy , 1993, Journal of internal medicine.
[8] V. Paradis,et al. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: A pathological analysis , 2009, Hepatology.
[9] N. Chalasani,et al. NAFLD fibrosis score: is it ready for wider use in clinical practice and for clinical trials? , 2013, Gastroenterology.
[10] E. Bjornsson,et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. , 2013, Gastroenterology.
[11] H. Makhlouf,et al. Pathologic criteria for nonalcoholic steatohepatitis: Interprotocol agreement and ability to predict liver‐related mortality , 2011, Hepatology.
[12] Henry Völzke,et al. Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma‐glutamyl transpeptidase levels , 2009, Hepatology.
[13] T. Saibara,et al. Clinical and pathological progression of non‐alcoholic steatohepatitis to hepatocellular carcinoma , 2012, Hepatology research : the official journal of the Japan Society of Hepatology.
[14] Joel Z Stengel,et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. , 2011, Gastroenterology.
[15] Randall G. Lee,et al. Nonalcoholic steatohepatitis: Tightening the morphological screws on a hepatic rambler , 1995, Hepatology.
[16] Jeanne M Clark,et al. The epidemiology of nonalcoholic fatty liver disease: a global perspective. , 2008, Seminars in liver disease.
[17] Greger Lindberg,et al. Decreased survival of subjects with elevated liver function tests during a 28‐year follow‐up , 2010, Hepatology.
[18] A. Frydén,et al. The clinical significance of slightly to moderately increased liver transaminase values in asymptomatic patients. , 1999, Scandinavian journal of gastroenterology.
[19] G. Targher,et al. Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients. , 2005, Diabetes.
[20] S. Grundy,et al. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. , 2005, American journal of physiology. Endocrinology and metabolism.
[21] Z. Younossi,et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. , 1999, Gastroenterology.
[22] A. Kotronen,et al. Fatty Liver: A Novel Component of the Metabolic Syndrome , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[23] Per Christoffersen,et al. Final results of a long-term, clinical follow-up in fatty liver patients , 2009, Scandinavian journal of gastroenterology.
[24] P Christoffersen,et al. Long term prognosis of fatty liver: risk of chronic liver disease and death , 2004, Gut.
[25] Chunhong Bai,et al. Long-term follow-up of patients with nonalcoholic fatty liver. , 2009, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[26] O. Cummings,et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease , 2005, Hepatology.
[27] S. Sanderson,et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. , 2005, Gastroenterology.
[28] A. Baranova,et al. Systematic review: the epidemiology and natural history of non‐alcoholic fatty liver disease and non‐alcoholic steatohepatitis in adults , 2011, Alimentary pharmacology & therapeutics.
[29] J. Heimbach,et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. , 2011, Gastroenterology.
[30] Vincent Wai-Sun Wong,et al. Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years , 2010, Gut.
[31] Ross J. Harris,et al. Gamma-Glutamyltransferase Is Associated With Incident Vascular Events Independently of Alcohol Intake: Analysis of the British Women’s Heart and Health Study and Meta-Analysis , 2007, Arteriosclerosis, thrombosis, and vascular biology.
[32] N. Kemmer,et al. Nonalcoholic Fatty Liver Disease Epidemic and Its Implications for Liver Transplantation , 2013, Transplantation.
[33] R. Hultcrantz,et al. Liver investigation in 149 asymptomatic patients with moderately elevated activities of serum aminotransferases. , 1986, Scandinavian journal of gastroenterology.
[34] Chris Day,et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference. , 2010, Journal of hepatology.
[35] M. Holmqvist,et al. Long‐term follow‐up of patients with NAFLD and elevated liver enzymes , 2006, Hepatology.
[36] G. Musso,et al. Meta-analysis: Natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity , 2011, Annals of medicine.
[37] T. Therneau,et al. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States , 2013, Hepatology.